Spectral AI Q2 loss narrows to $4.2M; FDA-cleared DeepView targets first sales by year-end

Spectral AI, Inc.

2026-Q2 EPS reported -$0.24 vs consensus -$0.14 ▼ miss (-74.3%)

Q2 2026 R&D revenue $3.5M vs $5.1M YoY; gross margin 31.6% vs 45.2% on BARDA cost-share.
Net loss $4.2M ($0.13/share) vs $8.0M loss ($0.31) YoY; adjusted EBITDA loss $(3.5)M vs $(1.7)M.
Cash $14.0M at June 30, 2026; drew $6.5M under Avenue Capital credit facility post-FDA clearance.
FDA De Novo clearance for DeepView burn indication received May 2026; first U.S. commercial sales targeted by year-end 2026.
March 2026 BARDA advanced funding of $31.7M; new CFO David McGuire and CCO Darcy Bajko appointed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.